Published in Carcinogenesis on April 29, 2004
Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect (2007) 1.66
Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet (2009) 1.17
Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control (2007) 0.97
High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J Nutr (2010) 0.97
Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. J Urol (2011) 0.90
Folate status and risk of colorectal polyps in African Americans. Dig Dis Sci (2007) 0.87
Polymorphisms of methylenetetrahydrofolate reductase and methionine synthase genes and bladder cancer risk: a case-control study with meta-analysis. Clin Exp Med (2008) 0.85
Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study. Environ Health (2012) 0.83
Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer. Diagn Pathol (2013) 0.79
Methylenetetrahydrofolate Reductase A1298C Polymorphism and Breast Cancer Risk: A Meta-analysis of 33 Studies. Ann Med Health Sci Res (2014) 0.78
Risk factors for colon cancer in Northeastern Thailand: interaction of MTHFR codon 677 and 1298 genotypes with environmental factors. J Epidemiol (2010) 0.76
Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population. Dis Markers (2017) 0.75
Lack of association between MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk: A meta-analysis of case-control studies. Biomed Rep (2014) 0.75
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet (2011) 9.49
Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. Am J Hum Genet (2008) 7.36
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst (2003) 5.09
Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet (2009) 4.56
Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol (2004) 4.51
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
The PhenX Toolkit: get the most from your measures. Am J Epidemiol (2011) 4.19
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst (2008) 3.67
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
The landscape of recombination in African Americans. Nature (2011) 3.06
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Effects of nativity, age at migration, and acculturation on smoking among adult Houston residents of Mexican descent. Am J Public Health (2005) 2.94
Stressing harms of physical inactivity to promote exercise. Lancet (2012) 2.93
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res (2009) 2.63
Focus on bladder cancer. Cancer Cell (2004) 2.59
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res (2008) 2.37
DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol (2011) 2.34
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol (2003) 2.30
Birthplace, years of residence in the United States, and obesity among Mexican-American adults. Obesity (Silver Spring) (2007) 2.28
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet (2006) 2.22
P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 2.21
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst (2002) 2.16
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst (2012) 2.13
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res (2008) 2.11
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev (2003) 2.09
An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) (2008) 2.05
Dietary phytoestrogens and lung cancer risk. JAMA (2005) 2.04
Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform (2003) 2.04
Lung cancer screening. J Natl Compr Canc Netw (2012) 2.00
Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res (2005) 1.98
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst (2011) 1.97
History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol (2009) 1.96
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma. Cancer Discov (2011) 1.87
A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res (2002) 1.87
A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) (2011) 1.86
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
The next generation of large-scale epidemiologic research: implications for training cancer epidemiologists. Am J Epidemiol (2014) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology (2006) 1.72
Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet (2004) 1.70
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int (2006) 1.70
Re: short telomere length, cancer survival, and cancer risk in 47 102 individuals. J Natl Cancer Inst (2013) 1.69
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer (2007) 1.69
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol (2009) 1.68
An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst (2002) 1.65
Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol (2007) 1.65